In adherence to strict Non-Disclosure Agreements, Sedulo is unable to disclose identifiable information regarding our clients.
A biopharma leader partnered with Sedulo on a multi-year competitive intelligence program to connect early clinical signals with commercial strategy. The engagement delivered continuous insights across 10 rare disease areas, enabling faster decisions, earlier warnings, and confident portfolio planning.
The Situation A global technology company with a stronghold in the enterprise segment was seeking to strengthen its performance in the small-to-mid-market (SMM) space. While large enterprise deals followed expected patterns, outcomes in the SMM segment were less predictable, revealing a need to better understand the buying behaviors and competitive dynamics influencing those decisions. Leadership engaged Sedulo Group to uncover:
Facing intensifying competition in the metabolic therapeutics arena, the pharma leader needed clear foresight into biosimilar threats, innovation pipelines, and competitor launch tactics. Through early-warning monitoring, primary intelligence, and deep landscape reporting, we helped them anticipate market shifts, align internal decision-makers, and fortify their leadership ahead of emerging disruptions.
When a rising competitor began making bold AI-centric claims, our client knew words weren’t enough, but facts were missing. Through buy-side research, we exposed that behind the AI messaging was an offshore manual data entry engine, arming the client with truthful insight to sharpen positioning, arm sales, and challenge false narratives.
A top pharmaceutical company partnered with Sedulo Group to leverage pharma competitive intelligence and outmaneuver competitors in a high-stakes product launch.
Entering a new market without the right intelligence is a costly risk. Learn how Sedulo Group equips companies with deep competitor, customer, and market insights to build confident, data-driven market entry strategies
